Integra (IART) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
In its upcoming report, Integra LifeSciences (IART) is predicted by Wall Street analysts to post quarterly earnings of $0.90 per share, reflecting a decline of 4.3% compared to the same period last year. Revenues are forecasted to be $398.81 million, representing a year-over-year increase of 0.2%.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
In light of this perspective, let's dive into the average estimates of certain Integra metrics that are commonly tracked and forecasted by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenue- Codman Specialty Surgical- Total' should arrive at $281.64 million. The estimate suggests a change of +6.4% year over year.
Analysts' assessment points toward 'Revenue- Tissue Technologies- Total' reaching $117.18 million. The estimate points to a change of -12.2% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenue- Tissue Technologies- Private Label' will likely reach $24.79 million. The estimate points to a change of -19.7% from the year-ago quarter.
Analysts predict that the 'Revenue- Codman Specialty Surgical- Instruments' will reach $64.33 million. The estimate indicates a year-over-year change of +8.3%.
According to the collective judgment of analysts, 'Revenue- Codman Specialty Surgical- Neurosurgery' should come in at $216.95 million. The estimate points to a change of +5.7% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenue- Tissue Technologies- Wound Reconstruction and Care' of $93.18 million. The estimate indicates a year-over-year change of -9.1%.
The average prediction of analysts places 'Geographic Revenues- United States' at $281.66 million. The estimate indicates a change of -4.2% from the prior-year quarter.
View all Key Company Metrics for Integra here>>>
Over the past month, shares of Integra have returned +6.9% versus the Zacks S&P 500 composite's +4.7% change. Currently, IART carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report
